VANTABIOHealthcare Research, Analytics & Technology
Vanta Bioscience Ltd — Cash Flow Statement
₹15.15
-10.72%
Vanta Bioscience Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -9.10 Cr | -0.72 Cr | -29.32 Cr | -11.90 Cr | — |
| Capital Expenditure | -6.69 Cr | -3.40 Cr | -28.69 Cr | -17.18 Cr | — |
| End Cash Position | 0.22 Cr | 0.16 Cr | 0.10 Cr | 0.22 Cr | — |
| Beginning Cash Position | 0.16 Cr | 0.10 Cr | 0.22 Cr | 2.65 Cr | — |
| Changes In Cash | 0.06 Cr | 0.06 Cr | -0.13 Cr | -2.37 Cr | — |
| Financing Cash Flow | 9.16 Cr | 0.69 Cr | 6.41 Cr | 9.53 Cr | — |
| Interest Paid Cff | -4.07 Cr | -5.75 Cr | -5.89 Cr | -2.35 Cr | — |
| Net Common Stock Issuance | 4.10 Cr | 2.65 Cr | 0.00 | 2.98 Cr | — |
| Net Issuance Payments Of Debt | 9.13 Cr | 3.79 Cr | 12.29 Cr | 8.90 Cr | — |
| Net Short Term Debt Issuance | 3.90 Cr | 1.11 Cr | 0.51 Cr | -0.33 Cr | — |
| Net Long Term Debt Issuance | 5.23 Cr | 2.69 Cr | 11.78 Cr | 9.23 Cr | — |
| Investing Cash Flow | -6.69 Cr | -3.31 Cr | -5.91 Cr | -17.18 Cr | — |
| Net Investment Purchase And Sale | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Purchase Of Investment | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Business Purchase And Sale | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Purchase Of Business | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Intangibles Purchase And Sale | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Purchase Of Intangibles | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net PPE Purchase And Sale | -6.69 Cr | -3.31 Cr | -5.91 Cr | -17.18 Cr | — |
| Sale Of PPE | 0.00 | 0.09 Cr | 22.78 Cr | 0.00 | — |
| Purchase Of PPE | -6.69 Cr | -3.40 Cr | -28.69 Cr | -17.18 Cr | — |
| Operating Cash Flow | -2.41 Cr | 2.68 Cr | -0.63 Cr | 5.28 Cr | — |
| Change In Working Capital | 1.74 Cr | 1.31 Cr | 1.08 Cr | 1.39 Cr | — |
| Change In Other Current Liabilities | -0.12 Cr | 3.07 Cr | 1.29 Cr | -0.30 Cr | — |
| Change In Other Current Assets | 0.06 Cr | 0.17 Cr | 0.74 Cr | 0.00 | — |
| Change In Inventory | 1.01 Cr | -0.36 Cr | 0.08 Cr | 2.53 Cr | — |
| Change In Receivables | 0.79 Cr | -1.58 Cr | -1.02 Cr | -0.84 Cr | — |
| Other Non Cash Items | 4.07 Cr | 5.75 Cr | 5.89 Cr | 2.35 Cr | — |
| Depreciation And Amortization | 4.42 Cr | 4.50 Cr | 2.67 Cr | 1.32 Cr | — |
| Depreciation | 4.42 Cr | 4.50 Cr | 2.67 Cr | 1.32 Cr | — |
| Gain Loss On Sale Of PPE | 0.00 | -0.04 Cr | 0.00 | 0.00 | — |
| Net Income From Continuing Operations | -12.63 Cr | -8.83 Cr | -10.26 Cr | 0.23 Cr | — |
| Issuance Of Capital Stock | — | 2.65 Cr | 0.00 | 2.98 Cr | 1.32 Cr |
| Other Cash Adjustment Outside Changein Cash | — | 10.00 | — | -0.06 Cr | -0.10 Cr |
| Common Stock Issuance | — | 2.65 Cr | 0.00 | 2.98 Cr | 1.32 Cr |
| Net Other Investing Changes | — | -10.00 | — | — | -10.00 |
| Amortization Cash Flow | — | 1.12 Cr | 0.57 Cr | — | — |
| Issuance Of Debt | — | — | 7.93 Cr | 6.80 Cr | 11.83 Cr |
| Long Term Debt Issuance | — | — | 7.93 Cr | 6.80 Cr | 11.83 Cr |
| Change In Payable | — | — | — | -0.30 Cr | 0.55 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Vanta Bioscience Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.